VCEL (Vericel) Moat Score: 6/10 (As of Jun. 27, 2026)


VCEL Vericel Corp VCEL
81 GF Score
Price $46.23
GF Value $54.29
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel Moat Score?

Vericel VCEL +7.76% 81 Moat Score is 6 as of Jun. 27, 2026. GuruFocus rates VCEL with a GF Score™ of 81/100 and a GF Value™ of $54.29 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,404 Biotechnology companies, Vericel ranks better than 98.93% on this metric.

Vericel has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Vericel has Narrow Moat: Vericel Corp possesses a strong narrow moat due to its valuable intellectual property and consistent innovation in regenerative medicine. However, the competitive biotech landscape limits its ability to achieve a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vericel might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Vericel  (NAS:VCEL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vericel Moat Score Related Terms

VCEL vs PVLA, TSHA, GENB: Moat Score Comparison

For the Biotechnology subindustry, Vericel's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vericel Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Moat Score distribution charts can be found below:

* The bar in red indicates where Vericel's Moat Score falls into.


VCEL
81GF Score
Vericel Corp VCEL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Vericel (VCEL) has a Moat Score of 6 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vericel ranks #15 out of 1404 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Vericel's Moat Score too high?
Vericel's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Vericel's value of 6 is 200% above this industry median. Based on the distribution chart, Vericel ranks #15 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Moat Score compare to PVLA and TSHA?
According to the Biotechnology industry distribution chart, Vericel ranks #15 out of 1404 companies for Moat Score. This places Vericel in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Vericel's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vericel's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vericel's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.29, compared to a current price of $46.23 — trading 14.8% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vericel (VCEL), the current Moat Score is 6 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vericel (VCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of $46.23 is trading 14.8% below its estimated GF Value™ of $54.29. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for VCEL:

  • Moat Score: 6
  • GF Value™: $54.29 vs. price of $46.23 (14.8% below fair value)
  • GF Score™: 81/100 with 7 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1404)

No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges ATQP:Germany
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score

Get the complete analysis for VCEL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.23
Price
$54.29
GF Value